Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 1/20 | 0.38 |
| ▸ | MMP12 | P39900 | 1/20 | 0.38 |
| ▸ | NR1I2 | O75469 | 5/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.35 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.33 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4144670 | 1.00 | PRKCA (0.38) | PRKCAMMP12NR1I2KCNH2CYP3A4 | |
| SCHEMBL4145785 | 0.90 | PRKCA (0.39) | PRKCAMMP12CSNK2A1 | |
| SCHEMBL4145782 | 0.90 | PRKCA (0.39) | PRKCAMMP12CSNK2A1 | |
| SCHEMBL894723 | 0.90 | PRKCA (0.48) | PRKCAMMP12NR1I2KCNH2CYP3A4 | |
| SCHEMBL4148439 | 0.89 | PRKCA (0.45) | PRKCAMMP12NR1I2CSNK2A1 | |
| SCHEMBL4148436 | 0.89 | PRKCA (0.45) | PRKCAMMP12NR1I2CSNK2A1 | |
| SCHEMBL4144340 | 0.88 | PRKCA (0.37) | PRKCAMMP12CSNK2A1 | |
| SCHEMBL4144335 | 0.88 | PRKCA (0.37) | PRKCAMMP12CSNK2A1 | |
| SCHEMBL4152682 | 0.88 | PRKCA (0.39) | PRKCAMMP12NR1I2KCNH2CYP3A4 | |
| SCHEMBL4149639 | 0.88 | PRKCA (0.39) | PRKCAMMP12NR1I2KCNH2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090136449-A1 | Tetracyclic Indole Derivatives as Antiviral Agents | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2009-05-28 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090136449-A1 | Tetracyclic Indole Derivatives as Antiviral Agents | IDO1, IDO2, ZC3HAV1 | PRKCA 4320/4885MMP12 3563/4885NR1I2 268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.